|
Age, years, median (range)
|
58 (16–79)
|
59 (16–79)
|
56 (16–79)
|
0.004
|
|
Sex, n (%)
|
|
Female
|
149 (44.3)
|
96 (51.6)
|
53 (35.3)
|
0.003
|
|
Male
|
187 (55.7)
|
90 (48.4)
|
97 (64.7)
| |
|
KPS, n (%)
|
|
≤ 70
|
172 (51.2)
|
104 (55.9)
|
68 (45.3)
|
0.156
|
|
80
|
82 (24.4)
|
41 (22)
|
41 (27.3)
| |
|
≥ 90
|
82 (24.4)
|
41 (22)
|
41 (27.3)
| |
|
Extent of resection, n (%)
|
|
Total
|
206 (61.3)
|
109 (58.6)
|
97 (64.7)
|
0.009
|
|
Subtotal/Partial
|
108 (32.1)
|
70 (37.6)
|
38 (25.3)
| |
|
Biopsy
|
22 (6.5)
|
7 (3.8)
|
15 (10)
| |
|
IDH1 mutation, n (%)
|
|
No
|
250 (74.4)
|
117 (62.9)
|
133 (88.7)
|
< 0.001
|
|
Yes
|
18 (5.4)
|
6 (3.2)
|
12 (8)
| |
|
unknown
|
68 (20.2)
|
63 (33.9)
|
5 (3.3)
| |
|
MGMT, n (%)
|
|
Unmethylated
|
212 (63.1)
|
115 (61.8)
|
97 (64.7)
|
0.592
|
|
Methylated
|
124 (36.9)
|
71 (38.2)
|
53 (35.3)
| |
|
Subventriclular zone, n (%)
|
|
Uninvolved
|
206 (61.3)
|
122 (65.6)
|
84 (56)
|
0.073
|
|
Involved
|
130 (38.7)
|
64 (34.4)
|
66 (44)
| |
|
PTV1 volume, cm3, median (range)
|
403 (71–1080)
|
422 (74–1080)
|
375 (71–1041)
|
<.001
|
|
PTV2 volume, cm3, median (range)
|
113 (6–475)
|
119 (12–475)
|
103 (6–468)
|
0.002
|
|
Total dose, Gy, median (range)
|
60 (41–72.5)
|
60 (54–70)
|
60 (41–72.5)
|
0.073
|
|
No. of fractionation, median (range)
|
30 (15–35)
|
30 (23–35)
|
30 (15–33)
|
<.001
|
|
Baseline TLC, /μL, median (range)
|
1370 (300–3740)
|
1365 (300–3740)
|
1385 (410–3640)
|
0.648
|
|
Baseline TLC, /μL, n (%)
|
|
< 1000
|
81 (24.1)
|
45 (24.2)
|
36 (24)
|
0.893
|
|
≥ 1000
|
255 (75.9)
|
141 (75.8)
|
114 (76)
| |
|
The cumulative dose of temozolomidea, mg/m2, median (range)
|
3588 (722–6267)
|
3497 (856–6267)
|
3684 (722–5599)
|
0.117
|
